10x Genomics Long Term Debt

10x Genomics posts a long-term debt of $70M as of March 2026. That compares with $71M in the prior-year period — down 0.8% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, 10x Genomics's long-term debt was $71M. The latest reading is $70M — a 0.8% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of 10x Genomics's financial statement story. At $70M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for TXG's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; 10x Genomics's other metric pages and overview cover the third.

Judging 10x Genomics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term debt easier to interpret. Start with $70M here, then scan peer and history charts to see if the gap is persistent.